NCT04588129View on ClinicalTrials.gov

Receptor Occupancy of LB-102 Using Positron Emission Tomography (PET) in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

January 5, 2021

Primary Completion Date

September 17, 2021

Study Completion Date

November 15, 2021

Conditions
Schizophrenia
Interventions
DRUG

LB-102

(N-Methyl amisulpride)

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

Sponsors
All Listed Sponsors
collaborator

Washington University School of Medicine

OTHER

lead

LB Pharmaceuticals Inc.

INDUSTRY